文献速递儿童感染儿童心血管与肾脏

儿童多系统炎症综合征糖皮质激素单药治疗的短期结局

Short-term Outcomes of Corticosteroid Monotherapy in Multisystem Inflammatory Syndrome in Children.
PubMed 文献 · JAMA Pediatr · 2022-01-01

这项回顾性队列研究纳入215例MIS-C患儿,比较初始糖皮质激素单药、IVIG单药或两者联用的短期结局。经倾向评分加权后,糖皮质激素单药与IVIG联合糖皮质激素的初始治疗失败率相似;糖皮质激素单药组住院和激素疗程更短。糖皮质激素单药对轻症MIS-C患者是合理选择。

要点

  • 糖皮质激素单药与IVIG联合糖皮质激素的初始治疗失败率相似。
  • 糖皮质激素单药组住院中位时间更短(5天 vs 6天),激素疗程更短(5天 vs 10天)。
  • 71%的糖皮质激素单药患者经10天或更短疗程后恢复。

核心结论

  • 糖皮质激素单药是部分MIS-C患者尤其是轻症患者的合理治疗选择。

研究设计与样本

  • 回顾性队列研究,纳入2020年3月至2021年2月三级儿科医院系统中符合CDC病例定义的MIS-C患者。
  • 215例纳入单变量分析,中位年龄8岁,135例(62.8%)为男孩。
  • 分组:糖皮质激素组69例,IVIG组31例,IVIG联合糖皮质激素组115例。
  • 倾向评分加权纳入179例(糖皮质激素组68例,联合组111例)。

主要发现

  • 糖皮质激素组患者就诊时疾病更轻。
  • 倾向评分加权后,糖皮质激素组与联合组的初始治疗失败率相似。
  • 初始治疗失败者中,联合组失败更可能基于实验室指标(OR 1.96,95%CI 1.07-3.60),更不可能基于心血管指标(OR 0.39,95%CI 0.2-0.76)。

关键数值与推荐

  • 初始治疗失败定义为治疗开始后24小时(ICU患者)或48小时(非ICU患者)因发热或实验室、心脏、非心脏临床因素恶化或无改善而升级治疗。
  • 免疫调节治疗需在最初24小时(ICU患者)或48小时(非ICU患者)内开始。

临床怎么用

  • 对于轻症MIS-C患者,可考虑糖皮质激素单药作为初始治疗。
  • 糖皮质激素单药可能缩短住院时间和激素疗程,但需结合病情严重程度个体化选择。

局限性

  • 回顾性研究设计。
  • 糖皮质激素组患者疾病更轻,可能存在选择偏倚。
  • IVIG单药组样本量较小(31例),未纳入倾向评分加权分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Optimal agents and duration of primary treatment for multisystem inflammatory syndrome in children (MIS-C) remain unclear. OBJECTIVE: To compare short-term patient outcomes based on initial treatment with corticosteroids, intravenous immunoglobulin (IVIG), or both. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included patients in a tertiary-care pediatric hospital system who had MIS-C per the Centers for Disease Control and Prevention case definition during the period March 2020 to February 2021. EXPOSURES: Immunomodulatory therapy within the first 24 hours (patients in the intensive care unit [ICU]) or 48 hours (non-ICU patients): corticosteroids alone, IVIG alone, and IVIG plus corticosteroids. MAIN OUTCOMES AND MEASURES: Primary outcome was failure of initial therapy, defined as therapy escalation due to fever or worsening or lack of improvement of laboratory, cardiac, or noncardiac clinical factors after 24 hours (ICU patients) or 48 hours (non-ICU patients) from time of therapy initiation, per clinician assessment. Secondary outcomes included presence of complications, cardiovascular outcomes, fever duration, length of hospital and ICU stays, corticosteroid use duration, and need for readmission. RESULTS: Among 228 eligible patients, 215 patients were included in the univariate analysis; median age was 8 years, and 135 (62.8%) were boys. There were 69 patients in the corticosteroids group, 31 patients in the IVIG group, and 115 patients in the IVIG plus corticosteroids group. Patients in the corticosteroids group had milder disease at presentation. After propensity score weighting including 179 patients (68 in the corticosteroids group and 111 in the IVIG plus corticosteroids group), rates of initial treatment failure were similar between groups. Among patients whose initial treatment failed, treatment failure in the IVIG plus corticosteroids group was more likely to be based on laboratory parameters (odds ratio [OR], 1.96; 95% CI, 1.07-3.60) and less likely to be based on cardiovascular markers (OR, 0.39; 95% CI, 0.2-0.76), per clinician assessment. Patients in the IVIG plus corticosteroids group had a longer median inpatient stay (6 vs 5 days; P = .001) and longer median corticosteroid course duration (10 vs 5 days; P = .04) compared with the corticosteroids group. Forty-nine patients (71% of 69 in the corticosteroids group) recovered after receiving corticosteroid monotherapy for 10 days or less. CONCLUSIONS AND RELEVANCE: Corticosteroid monotherapy is a reasonable management option for a subset of patients with MIS-C, particularly those with mild disease.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Villacis-Nunez DS, Jones K, Jabbar A, et al. Short-term Outcomes of Corticosteroid Monotherapy in Multisystem Inflammatory Syndrome in Children. JAMA Pediatr. 2022. PMID: 35344042. doi:10.1001/jamapediatrics.2022.0292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。